Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Janux Therapeutics stock

Learn how to easily invest in Janux Therapeutics stock.

Janux Therapeutics is a biotechnology business based in the US. Janux Therapeutics shares (JANX) are listed on the NASDAQ and all prices are listed in US Dollars. Janux Therapeutics employs 60 staff and has a trailing 12-month revenue of around $8.6 million.

How to buy Janux Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – JANX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for options trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Janux Therapeutics stock price (NASDAQ: JANX)

Use our graph to track the performance of JANX stocks over time.

Janux Therapeutics shares at a glance

Information last updated 2023-03-16.
Latest market close$11.53
52-week range$9.39 - $23.64
50-day moving average $17.80
200-day moving average $14.64
Wall St. target price$29.67
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.33

Buy Janux Therapeutics stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 7 of 7
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
Stocks, ETFs, Cryptocurrency, Alternatives, Treasury Bills
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Diversify your portfolio by trading stocks, ETFs, T-Bills, crypto, rare collectibles and more.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs, Treasury Bills
Get $50 - $700
when you open and fund an account with $10,000 - $250,000+
Stocks, Bonds, Options, Mutual funds, ETFs, Futures
Get up to $600 or more
when you open and fund a new account.
E*TRADE offers commission-free stocks, access to mutual funds and advanced trading tools. Other fees apply.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Janux Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Janux Therapeutics price performance over time

Historical closes compared with the close of $11.53 from 2023-03-21

1 week (2023-03-14) -19.71%
1 month (2023-02-22) -32.53%
3 months (2022-12-22) -4.24%
6 months (2022-09-22) -13.44%
1 year (2022-03-22) -26.04%
2 years (2021-03-18) N/A
3 years (2020-03-18) N/A
5 years (2018-03-18) N/A

Janux Therapeutics financials

Revenue TTM $8.6 million
Gross profit TTM $-44,829,000
Return on assets TTM -11.27%
Return on equity TTM -18.36%
Profit margin 0%
Book value $7.71
Market capitalisation $553.9 million

TTM: trailing 12 months

Janux Therapeutics share dividends

We're not expecting Janux Therapeutics to pay a dividend over the next 12 months.

Janux Therapeutics overview

Janux Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California. .

Frequently asked questions

What percentage of Janux Therapeutics is owned by insiders or institutions?
Currently 10.959% of Janux Therapeutics shares are held by insiders and 101.586% by institutions.
How many people work for Janux Therapeutics?
Latest data suggests 60 work at Janux Therapeutics.
When does the fiscal year end for Janux Therapeutics?
Janux Therapeutics's fiscal year ends in December.
Where is Janux Therapeutics based?
Janux Therapeutics's address is: 11099 North Torrey Pines Road, La Jolla, CA, United States, 92037
What is Janux Therapeutics's ISIN number?
Janux Therapeutics's international securities identification number is: US47103J1051

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site